日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacies of Sequenced Monotherapies of Mycobacterium avium Lung Infection in Mouse

小鼠分枝杆菌肺部感染序贯单药疗法的疗效

Howe, Ruth A; Rimal, Binayak; Khandelwal, Jay; Panthi, Chandra M; Lamichhane, Gyanu

Combinations comprising dual β-lactams and a β-lactamase inhibitor achieve optimal synergistic inhibition of Mycobacterium abscessus growth

由两种β-内酰胺类抗生素和一种β-内酰胺酶抑制剂组成的组合可实现对脓肿分枝杆菌生长的最佳协同抑制。

Rimal, Binayak; Xie, Yi; Panthi, Chandra M; Devlin, Kaylyn L; Beatty, Kimberly E; Lamichhane, Gyanu

A BALB/c mouse model of Mycobacterium abscessus lung infection based on once-weekly cyclophosphamide administration.

基于每周一次环磷酰胺给药的BALB/c小鼠脓肿分枝杆菌肺部感染模型

Rimal Binayak, Panthi Chandra M, Howe Ruth A, Lamichhane Gyanu

Oral oxaborole MRX-5 exhibits efficacy against pulmonary Mycobacterium abscessus in mouse

口服氧硼烷类化合物MRX-5对小鼠肺部脓肿分枝杆菌感染具有疗效。

Rimal, Binayak; Howe, Ruth A; Panthi, Chandra M; Wang, Wen; Lamichhane, Gyanu

Efficacy of epetraborole against Mycobacteroides abscessus in a mouse model of lung infection

在小鼠肺部感染模型中,依佩曲硼罗对脓肿分枝杆菌的疗效

Rimal, Binayak; Lippincott, Christopher K; Panthi, Chandra M; Xie, Yi; Keepers, Tiffany R; Alley, Mrk; Lamichhane, Gyanu

Microbiological profile, preclinical pharmacokinetics and efficacy of CRS0393, a novel antimycobacterial agent targeting MmpL3.

CRS0393 是一种新型抗分枝杆菌药物,靶向 MmpL3,其微生物学特征、临床前药代动力学和疗效研究

Ochsner Urs A, De Groote Mary A, Jarvis Thale C, Liu Hang, Youmans Tessa, Hoang Teresa, Ribble Wendy, Day Joshua, Li Wei, Pearce Camron, Walz Amanda, Panthi Chandra M, Rimal Binayak, Stevens Casey M, Zgurskaya Helen I, Jackson Mary, Ordway Diane, Gonzalez-Juarrero Mercedes, Sun Xicheng, Lamichhane Gyanu, Mason Clifford

T405, a New Penem, Exhibits In Vivo Efficacy against M. abscessus and Synergy with β-Lactams Imipenem and Cefditoren

新型培南类抗生素T405在体内对脓肿分枝杆菌显示出疗效,并与β-内酰胺类抗生素亚胺培南和头孢地托仑具有协同作用。

Rimal, Binayak; Batchelder, Hunter R; Story-Roller, Elizabeth; Panthi, Chandra M; Tabor, Chavis; Nuermberger, Eric L; Townsend, Craig A; Lamichhane, Gyanu